GH Research (GHRS.US) Price Target 2026/2027: 35% Upside – Rating and Stock Analysis
GH Research Price Target 2026: Analysts See 36% Upside
The average price target for GH Research is $40.00. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 35,55% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.Is GH Research overvalued or undervalued?
GH Research is currently undervalued with a gap of 35.5% relative to the price target.
The current price is $29.51, which places GH Research in the undervalued category. The stock is considered undervalued when the price is below $36.00, and overvalued when the price exceeds $44.00.
The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For GH Research, the fair value range lies between $36.00 and $44.00.
Analyst Ratings for GH Research stock in 2026: Strong Buy
8 analysts cover GH Research. There is broad agreement on a positive view — 100% recommend buying. The average price target is $40.00, which gives an upside of 35.5% from the current price.
About GH Research – Bioteknologi
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. Read more about the companyKey Figures for GH Research
What kind of stock is GH Research?
GH Research is classified as a momentum stock with a momentum score in the top 2% of all stocks. The price has risen 0.0% over the long term.
Score Overview for GH Research
📈 Valuation
The P/B ratio is 7.3.
🏦 Financial Health
The Piotroski score is 2 out of 9 — weak financial health, be careful. Altman Z2 is 25.98 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 5.2% — low debt, a solid balance sheet.
🚀 Momentum & Short Interest
Short interest is 7.24% — elevated, some investors are betting on a decline.
GH Research Short Selling 2026: 7.2% Sold Short
What does this mean for you as an investor?
A short interest of 7.2% means that 7.2% of the freely traded shares in GH Research have been borrowed and sold by investors betting on falling prices.
The next potential catalyst is the earnings report on 8/6/2026. With a short interest of 7.2%, the report can trigger considerable volatility.
Data is updated daily based on official filings with the SEC.
GH Research Earnings – ⚡ Reporting TODAY 8/6/2026
The next earnings date for GH Research is not yet available. Check the company's investor calendar for more information.Technical Analysis of GH Research 2026 – Signal: Strong Buy
Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.
Trend Analysis of GH Research PLC
GH Research PLC is in a short-term uptrend. The price of $29.13 is 4.7% above the 20-day average ($27.83). Medium term, the picture is positive: the price is 15.0% above the 50-day average ($25.33). Long term, the stock is 60.4% above the 200-day average ($18.16), which confirms a long-term uptrend.
Golden Cross: The 50-day average (25.33) is above the 200-day average (18.16), which is a classic bullish signal for GH Research PLC.
Is GH Research PLC overbought or oversold?
GH Research PLC has an RSI of 62.7. The stock shows positive momentum in the upper part of the neutral zone. Combined with the positive trend, this supports the bullish picture.
MACD Analysis for GH Research PLC
Daily MACD: MACD is positive (0.939), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is below the signal line (0.999) by 0.060, which suggests the positive momentum is fading – the trend could be turning.
Weekly MACD: MACD5 is positive (3.307), which indicates a broader bullish long-term trend. MACD5 is above the signal line (2.646) by 0.661, which confirms rising long-term momentum.
Overall MACD assessment: Both the daily and weekly trend are bullish (MACD positive). However, momentum shows signs of weakening on a daily basis. Watch whether the trend holds.
Risk Profile for GH Research PLC
GH Research PLC has an annual standard deviation of 72.0%, which classifies the stock as extreme risk. Only risk-tolerant investors should consider this stock, because the price swings can be very large.
Overall Technical Conclusion for GH Research PLC
Trend: Positive. The price trades above SMA50 and SMA200.
MACD trend (zero line): Daily bullish (0.939). Weekly bullish (3.307).
MACD momentum (signal): Daily falling. Weekly rising.
RSI: 62.7 – neutral.
Technical signal: Strong Buy
The price is in an uptrend (above SMA50/SMA200) and MACD is positive on both a daily and weekly basis. Trend and MACD trend confirm each other – the strongest technical buy signal.